Regeneron Pharmaceuticals Inc (NASDAQ:REGN) EVP Neil Stahl sold 7,364 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $338.52, for a total transaction of $2,492,861.28. Following the completion of the sale, the executive vice president now owns 21,150 shares in the company, valued at approximately $7,159,698. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Shares of NASDAQ:REGN opened at $348.30 on Thursday. The stock has a market capitalization of $37.54 billion, a price-to-earnings ratio of 17.59, a PEG ratio of 1.50 and a beta of 1.14. Regeneron Pharmaceuticals Inc has a 1-year low of $271.37 and a 1-year high of $442.00. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.27 and a current ratio of 4.03. The company has a 50 day moving average price of $302.71 and a 200 day moving average price of $304.44.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, November 5th. The biopharmaceutical company reported $6.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $5.13 by $1.54. The firm had revenue of $2.05 billion during the quarter, compared to analysts’ expectations of $1.98 billion. Regeneron Pharmaceuticals had a net margin of 28.13% and a return on equity of 24.85%. The firm’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period last year, the firm posted $5.87 earnings per share. On average, sell-side analysts expect that Regeneron Pharmaceuticals Inc will post 19.62 EPS for the current fiscal year.
REGN has been the subject of several recent analyst reports. Guggenheim upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price objective for the company from $355.00 to $403.00 in a report on Monday, September 23rd. Morgan Stanley increased their price objective on shares of Regeneron Pharmaceuticals from $375.00 to $387.00 and gave the company an “equal weight” rating in a report on Wednesday, November 6th. Citigroup upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price objective for the company from $340.00 to $420.00 in a report on Wednesday, November 6th. SunTrust Banks initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday. They issued a “hold” rating and a $360.00 price objective for the company. Finally, Bank of America initiated coverage on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 16th. They issued a “neutral” rating and a $325.00 price objective for the company. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $384.63.
Large investors have recently modified their holdings of the stock. Altfest L J & Co. Inc. bought a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $538,000. Bank of Nova Scotia lifted its position in shares of Regeneron Pharmaceuticals by 25.4% in the 2nd quarter. Bank of Nova Scotia now owns 21,832 shares of the biopharmaceutical company’s stock valued at $6,833,000 after acquiring an additional 4,420 shares in the last quarter. KBC Group NV lifted its position in shares of Regeneron Pharmaceuticals by 25.6% in the 2nd quarter. KBC Group NV now owns 48,628 shares of the biopharmaceutical company’s stock valued at $15,221,000 after acquiring an additional 9,912 shares in the last quarter. Calamos Advisors LLC lifted its position in shares of Regeneron Pharmaceuticals by 2.1% in the 2nd quarter. Calamos Advisors LLC now owns 11,911 shares of the biopharmaceutical company’s stock valued at $3,728,000 after acquiring an additional 248 shares in the last quarter. Finally, Gargoyle Investment Advisor L.L.C. lifted its position in shares of Regeneron Pharmaceuticals by 6.8% in the 2nd quarter. Gargoyle Investment Advisor L.L.C. now owns 1,526 shares of the biopharmaceutical company’s stock valued at $478,000 after acquiring an additional 97 shares in the last quarter. Hedge funds and other institutional investors own 66.61% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Article: Lock-Up Period Expiration
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.